PolyPid Ltd. (NASDAQ:PYPD) Given Average Rating of “Moderate Buy” by Analysts

Shares of PolyPid Ltd. (NASDAQ:PYPD) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $12.25.

PYPD has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of PolyPid from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of PolyPid in a research note on Monday, December 29th. Roth Mkm reduced their target price on PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of PolyPid in a research report on Wednesday, February 11th. Finally, Citigroup reissued a “market outperform” rating on shares of PolyPid in a research note on Monday, December 1st.

PolyPid Stock Performance

NASDAQ:PYPD opened at $4.18 on Friday. PolyPid has a 52 week low of $2.30 and a 52 week high of $5.12. The firm’s fifty day moving average is $4.41 and its 200-day moving average is $3.84. The firm has a market cap of $66.46 million, a P/E ratio of -1.85 and a beta of 1.52.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings data on Wednesday, February 11th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.07). As a group, sell-side analysts anticipate that PolyPid will post -1.79 earnings per share for the current year.

Institutional Trading of PolyPid

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its position in shares of PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after buying an additional 3,500 shares during the last quarter. HighTower Advisors LLC purchased a new stake in PolyPid in the fourth quarter worth $44,000. XTX Topco Ltd boosted its holdings in PolyPid by 50.0% in the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after acquiring an additional 10,888 shares in the last quarter. Jane Street Group LLC purchased a new position in PolyPid during the 4th quarter valued at $66,000. Finally, Lumbard & Kellner LLC bought a new position in PolyPid in the 2nd quarter worth $135,000. 26.47% of the stock is owned by institutional investors.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.